Share Facebook Twitter Email The large phase 3 DETERMINATION trial has cemented lenalidomide, bortezomib, and dexamethasone (RVd) with stem cell mobilization followed by lenalidomide until progression as the standard of care for newly-diagnosed multiple myeloma. Citation(s) ASCO 2022 Immunotherapy